## Penelope Korkolopoulou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11797432/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Laying the groundwork for the Biobank of Rare Malignant Neoplasms at the service of the Hellenic Network of Precision Medicine on Cancer. International Journal of Oncology, 2022, 60, .	3.3	5
2	Polycystinâ€1 regulates cell proliferation and migration through AKT/mTORC2 pathway in a human craniosynostosis cell model. Journal of Cellular and Molecular Medicine, 2022, 26, 2428-2437.	3.6	7
3	Methylation analysis of APC, AXIN2, DACT1, RASSF1A and MGMT gene promoters in non-small cell lung cancer. Pathology Research and Practice, 2022, 234, 153899.	2.3	2
4	Symptomatic ovarian involvement as the initial presentation of primary mediastinal large b-cell lymphoma. Gynecologic Oncology Reports, 2022, 41, 100988.	0.6	0
5	Polycystin-1 induces activation of the PI3K/AKT/mTOR pathway and promotes angiogenesis in renal cell carcinoma. Cancer Letters, 2020, 489, 135-143.	7.2	18
6	Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 207-217.	2.8	21
7	A Unique Case of Primary Extranodal Marginal Zone Lymphoma of the Anal Canal. Acta Haematologica, 2019, 142, 87-91.	1.4	4
8	Polycystin-1 downregulation induces ERK-dependent mTOR pathway activation in a cellular model of psoriasis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3468-3476.	3.8	13
9	Comprehensive expression analysis of TNF-related apoptosis-inducing ligand and its receptors in colorectal cancer: Correlation with MAPK alterations and clinicopathological associations. Pathology Research and Practice, 2018, 214, 826-834.	2.3	5
10	Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance. Blood, 2018, 132, 666-670.	1.4	44
11	Thioredoxin-1, chemokine (C-X-C motif) ligand-9 and interferon-Î <sup>3</sup> expression in the neoplastic cells and macrophages of Hodgkin lymphoma: clinicopathologic correlations and potential prognostic implications. Leukemia and Lymphoma, 2017, 58, 2227-2239.	1.3	4
12	Detection of L265P <i>MYDâ€88</i> mutation in a series of clonal Bâ€cell lymphocytosis of marginal zone origin (CBLâ€MZ). Hematological Oncology, 2017, 35, 542-547.	1.7	10
13	Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients. World Journal of Urology, 2017, 35, 411-419.	2.2	20
14	Recent Advances in Aggressive Large B-cell Lymphomas: A Comprehensive Review. Advances in Anatomic Pathology, 2016, 23, 202-243.	4.3	15
15	No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab. Leukemia and Lymphoma, 2016, 57, 2705-2708.	1.3	5
16	Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome. Scientific Reports, 2016, 6, 21252.	3.3	6
17	Additive effects of dietary glycotoxins and androgen excess on the kidney of a female rat model. Alexandria Journal of Medicine, 2016, 52, 159-168.	0.6	0
18	Clinical significance of AGE-RAGE axis in colorectal cancer: associations with glyoxalase-I, adiponectin receptor expression and prognosis. BMC Cancer, 2016, 16, 174.	2.6	55

#	Article	IF	CITATIONS
19	Advanced glycation end products upregulate lysyl oxidase and endothelin-1 in human aortic endothelial cells via parallel activation of ERK1/2–NF-κB and JNK–AP-1 signaling pathways. Cellular and Molecular Life Sciences, 2016, 73, 1685-1698.	5.4	70
20	Impact of Androgen and Dietary Advanced Glycation End Products on Female Rat Liver. Cellular Physiology and Biochemistry, 2015, 37, 1134-1146.	1.6	9
21	Immunohistochemical and molecular analysis of PI3K/ <scp>AKT</scp> /m <scp>TOR</scp> pathway in esophageal carcinoma. Apmis, 2015, 123, 639-647.	2.0	18
22	Multifocal Bilateral Breast Cancer and Breast Follicular Lymphoma: A Simple Coincidence?. Journal of Breast Cancer, 2015, 18, 296.	1.9	7
23	Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations. PLoS ONE, 2015, 10, e0133859.	2.5	31
24	Dietary glycotoxins induce RAGE and VEGF up-regulation in the retina of normal rats. Experimental Eye Research, 2015, 137, 1-10.	2.6	13
25	Neuropathological assessments of the pathology in frontotemporal lobar degeneration with TDP43-positive inclusions: an inter-laboratory study by the BrainNet Europe consortium. Journal of Neural Transmission, 2015, 122, 957-972.	2.8	25
26	Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) with concurrent high grade component at diagnosis: clinico-pathologic features and treatment strategy. Leukemia and Lymphoma, 2015, 56, 3230-3232.	1.3	1
27	Polycystinâ€1 and polycystinâ€2 are involved in the acquisition of aggressive phenotypes in colorectal cancer. International Journal of Cancer, 2015, 136, 1515-1527. Immunohistochemical Analysis of IL-6, IL-8/CXCR2 Axis, <mml:math< td=""><td>5.1</td><td>41</td></mml:math<>	5.1	41
28	xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"> <mml:msup><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mtext>Ty and SOCS-3 in Lymph Nodes from Patients with Chronic Lymphocytic Leukemia: Correlation between Microvascular Characteristics and Prognostic Significance. BioMed Research International, 2014,</mml:mtext></mml:mrow></mml:msup>	r <td>ext&gt;17</td>	ext>17
29	2014, 1-13. New Insights into Monoclonal B-Cell Lymphocytosis. BioMed Research International, 2014, 2014, 1-11.	1.9	17
30	Highâ€frequency <i>p16</i> <scp><sup><i>INK</i></sup></scp> <sup><i>4A</i></sup> promoter methylation is associated with histone methyltransferase <scp>SETDB</scp> 1 expression in sporadic cutaneous melanoma. Experimental Dermatology, 2014, 23, 332-338.	2.9	33
31	The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma. BMC Cancer, 2014, 14, 149.	2.6	18
32	Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 473-485.	2.8	46
33	Clinical Aspects of Malt Lymphomas. Current Hematologic Malignancy Reports, 2014, 9, 262-272.	2.3	17
34	Apoptotic and proliferative characteristics of proliferation centers in lymph node sections of patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2014, 55, 571-582.	1.3	7
35	Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity?. Blood, 2014, 123, 1199-1206.	1.4	76
36	Impact of diet-induced obesity in male mouse reproductive system: The role of advanced glycation end product–receptor for advanced glycation end product axis. Experimental Biology and Medicine, 2014, 239, 937-947.	2.4	7

#	Article	IF	CITATIONS
37	Isolated central nervous system relapses in primary mediastinal large Bâ€cell lymphoma after CHOPâ€like chemotherapy with or without Rituximab. Hematological Oncology, 2013, 31, 10-17.	1.7	30
38	A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides. Journal of the American Academy of Dermatology, 2013, 69, 375-384.	1.2	20
39	A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Oncology Reports, 2013, 30, 623-636.	2.6	41
40	TRAIL and osteoprotegerin (OPG) expression in bladder urothelial carcinoma: correlation with clinicopathological parameters and prognosis. Pathology, 2013, 45, 138-144.	0.6	9
41	Treatment of Splenic Marginal Zone Lymphoma With Rituximab Monotherapy: Progress Report and Comparison With Splenectomy. Oncologist, 2013, 18, 190-197.	3.7	77
42	Association of aberrant DNA methylation with clinicopathological features in breast cancer. Oncology Reports, 2012, 27, 1630-8.	2.6	50
43	The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas. Neurology Research International, 2012, 2012, 1-13.	1.3	3
44	Replication Protein A in Nonearly Ovarian Adenocarcinomas. International Journal of Gynecological Pathology, 2012, 31, 319-327.	1.4	16
45	Autoimmune hemolytic anemia and autoimmune thrombocytopenia at diagnosis and during follow-up of Hodgkin lymphoma. Leukemia and Lymphoma, 2012, 53, 1481-1487.	1.3	21
46	The need to unify neuropathological assessments of vascular alterations in the ageing brain. Experimental Gerontology, 2012, 47, 825-833.	2.8	57
47	A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3â€kinase/vâ€akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. BJU International, 2012, 110, E1237-48.	2.5	52
48	Reduced Ovarian Glyoxalase-I Activity by Dietary Glycotoxins and Androgen Excess: A Causative Link to Polycystic Ovarian Syndrome. Molecular Medicine, 2012, 18, 1183-1189.	4.4	43
49	Expression of Interleukin-8 Receptor CXCR2 and Suppressor of Cytokine Signaling-3 in Astrocytic Tumors. Molecular Medicine, 2012, 18, 379-388.	4.4	15
50	Phosphorylated 4Eâ€binding protein 1 (pâ€4Eâ€BP1): a novel prognostic marker in human astrocytomas. Histopathology, 2012, 61, 293-305.	2.9	46
51	ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics. World Journal of Surgical Oncology, 2012, 10, 47.	1.9	31
52	Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. Leukemia and Lymphoma, 2011, 52, 387-393.	1.3	35
53	Prognostic significance of IL-8-STAT-3 pathway in astrocytomas: Correlation with IL-6, VEGF and microvessel morphometry. Cytokine, 2011, 55, 387-395.	3.2	45
54	Replication protein A: a reliable biologic marker of prognostic and therapeutic value in human astrocytic tumors. Human Pathology, 2011, 42, 1545-1553.	2.0	13

#	Article	IF	CITATIONS
55	Prognostic significance of replication protein A (RPA) expression levels in bladder urothelial carcinoma. BJU International, 2011, 108, E59-65.	2.5	31
56	Peripheral T cell lymphomas with follicular T helper phenotype: a new basket or a distinct entity? Revising Karl Lennert's personal archive. Histopathology, 2011, 59, 679-691.	2.9	51
57	Revising the historical collection of epithelioid cell-rich lymphomas of the Kiel Lymph Node Registry: what is Lennert's lymphoma nowadays?. Histopathology, 2011, 59, 1173-1182.	2.9	47
58	Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 749-759.	2.8	15
59	Immunohistochemical expression and prognostic significance of CCND3, MCM2 and MCM7 in Hodgkin lymhoma. Anticancer Research, 2011, 31, 3585-94.	1.1	24
60	D-type cyclins in superficial and muscle-invasive bladder urothelial carcinoma: correlation with clinicopathological data and prognostic significance. Journal of Cancer Research and Clinical Oncology, 2010, 136, 1563-1571.	2.5	22
61	Lysyl oxidase interacts with AGE signalling to modulate collagen synthesis in polycystic ovarian tissue. Journal of Cellular and Molecular Medicine, 2010, 14, 2460-2469.	3.6	57
62	High Incidence of MGMT and RARβ Promoter Methylation in Primary Glioblastomas: Association with Histopathological Characteristics, Inflammatory Mediators and Clinical Outcome. Molecular Medicine, 2010, 16, 1-9.	4.4	48
63	Assessment of β-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathologica, 2009, 117, 309-320.	7.7	143
64	Staging/typing of Lewy body related α-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathologica, 2009, 117, 635-652.	7.7	249
65	Analysis of interleukin (IL)-8 expression in human astrocytomas: Associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry. Human Immunology, 2009, 70, 391-397.	2.4	47
66	Early‣tage Gastric MALT Lymphoma: Is It a Truly Localized Disease?. Oncologist, 2009, 14, 148-154.	3.7	13
67	Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations. Pathology, 2009, 41, 327-334.	0.6	23
68	Inter-laboratory comparison of neuropathological assessments of β-amyloid protein: a study of the BrainNet Europe consortium. Acta Neuropathologica, 2008, 115, 533-546.	7.7	86
69	Clinical significance of nuclear factor (NF)-κB levels in urothelial carcinoma of the urinary bladder. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 452, 295-304.	2.8	52
70	Staging of Neurofibrillary Pathology in Alzheimer's Disease: A Study of the BrainNet Europe Consortium. Brain Pathology, 2008, 18, 484-496.	4.1	361
71	Expression of nuclear factor-κB in human astrocytomas: relation to plκBa, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival. Human Pathology, 2008, 39, 1143-1152.	2.0	49
72	Non-gastric extra-nodal marginal zone lymphomas–a single centre experience on 76 patients. Leukemia and Lymphoma, 2008, 49, 2308-2315.	1.3	32

#	Article	IF	CITATIONS
73	Discerning the Ancestry of European Americans in Genetic Association Studies. PLoS Genetics, 2008, 4, e236.	3.5	281
74	Topoisomerase IIα Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma. Clinical Cancer Research, 2008, 14, 1759-1766.	7.0	24
75	Assessment of α-Synuclein Pathology: A Study of the BrainNet Europe Consortium. Journal of Neuropathology and Experimental Neurology, 2008, 67, 125-143.	1.7	73
76	TGF-βRII, BAX, IGFIIR, caspase-5, hMSH3 and hMSH6 alterations are not associated with microsatellite instability or p53 mutations in invasive urothelial carcinoma of the urinary bladder. Pathology, 2007, 39, 425-432.	0.6	3
77	Expression and Prognostic Significance of Cyclin D3 in Ovarian Adenocarcinomas. International Journal of Gynecological Pathology, 2007, 26, 410-417.	1.4	11
78	Comparative analysis of peripheral and localised cytokine secretion in glioblastoma patients. Cytokine, 2007, 39, 99-105.	3.2	62
79	Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX. Human Pathology, 2007, 38, 629-638.	2.0	47
80	Replication protein A is an independent prognostic indicator with potential therapeutic implications in colon cancer. Modern Pathology, 2007, 20, 159-166.	5.5	78
81	Accumulation of dietary glycotoxins in the reproductive system of normal female rats. Journal of Molecular Medicine, 2007, 85, 1413-1420.	3.9	84
82	Cyclooxygenase-2 expression in astrocytomas. Relationship with microvascular parameters, angiogenic factors expression and survival. Molecular and Cellular Biochemistry, 2007, 295, 75-83.	3.1	31
83	Application of the ELISPOT method for comparative analysis of interleukin (IL)-6 and IL-10 secretion in peripheral blood of patients with astroglial tumors. Molecular and Cellular Biochemistry, 2007, 304, 343-351.	3.1	65
84	Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochemistry and Cell Biology, 2007, 127, 581-589.	1.7	151
85	Expression of nuclear factor κB in human gastric carcinoma: relationship with IκBa and prognostic significance. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 450, 519-527.	2.8	37
86	Interlaboratory Comparison of Assessments of Alzheimer Disease-Related Lesions: A Study of the BrainNet Europe Consortium. Journal of Neuropathology and Experimental Neurology, 2006, 65, 740-757.	1.7	95
87	Analysis of PRNP Gene Codon 129 Polymorphism in the Greek Population. European Journal of Epidemiology, 2006, 21, 211-215.	5.7	8
88	Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. European Journal of Haematology, 2006, 77, 300-303.	2.2	47
89	Rituximab-CHOP (R-CHOP) and Radiotherapy (RT) for Primary Mediastinal Large B-Cell Lymphoma (PMLBCL) Blood, 2006, 108, 2745-2745.	1.4	4
90	Z-Guggulsterone Downregulates Survivin and Induces Cell Death in Large B Cell Lymphoma Cells In Vitro Blood, 2006, 108, 4752-4752.	1.4	0

#	Article	IF	CITATIONS
91	B-Chronic Lymphoproliferative Disorders (BCLD) Presenting with Splenomegaly: Differential Diagnosis and Outcome Blood, 2006, 108, 4655-4655.	1.4	0
92	Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. Blood, 2005, 105, 1875-1880.	1.4	61
93	Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators. Human Pathology, 2005, 36, 899-907.	2.0	63
94	Retrospective Analysis of 41 Consecutive Patients with Non Gastrointestinal (GI) Extranodal Marginal Zone B-Cell Lymphoma (EMZL): Correlation of Clinical Characteristics and Outcome with Disease Localization Blood, 2005, 106, 4785-4785.	1.4	0
95	c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Urology, 2004, 63, 1198-1204.	1.0	69
96	Reduced retinoblastoma gene protein to ki-67 ratio is an adverse prognostic indicator for ovarian adenocarcinoma patients. Gynecologic Oncology, 2003, 88, 369-378.	1.4	26
97	A morphometric study of bone marrow angiogenesis in hairy cell leukaemia with clinicopathological correlations. British Journal of Haematology, 2003, 122, 900-910.	2.5	17
98	Differential Expression of bcl-2 Family Proteins in Bladder Carcinomas. European Urology, 2002, 41, 274-283.	1.9	52
99	The Combined Evaluation of p27Kip1 and Ki-67 Expression Provides Independent Information on Overall Survival of Ovarian Carcinoma Patients. Gynecologic Oncology, 2002, 85, 404-414.	1.4	47
100	Morphometric microvascular characteristics predict prognosis in superficial and invasive bladder cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 438, 603-611.	2.8	43
101	Apoptosis detected with monoclonal antibody to single-stranded DNA is a predictor of recurrence in intracranial meningiomas. Journal of Neuro-Oncology, 2001, 55, 1-9.	2.9	17
102	Prognostic Implications of Aberrations in p16/pRb Pathway in Urothelial Bladder Carcinomas: A Multivariate Analysis Including p53 Expression and Proliferation Markers. European Urology, 2001, 39, 167-177.	1.9	41
103	WAF1/p21 Protein Expression Is an Independent Prognostic Indicator in Superficial and Invasive Bladder Cancer. Applied Immunohistochemistry & Molecular Morphology, 2000, 8, 285-292.	2.0	29
104	WAF1/p21 Protein Expression Is an Independent Prognostic Indicator in Superficial and Invasive Bladder Cancer. Applied Immunohistochemistry and Molecular Morphology, 2000, 8, 285-292.	1.2	0
105	Apoptosis in bladder carcinomas detected with monoclonal antibody to single-stranded DNA: relation to cell cycle regulators and survival. Urology, 2000, 56, 516-520.	1.0	19
106	Expression of retinoblastoma gene product and p21 (WAF1/Cip 1) protein in gliomas: correlations with proliferation markers, p53 expression and survival. Acta Neuropathologica, 1998, 95, 617-624.	7.7	43
107	The Role of p53, MDM2 and c-erb B-2 Oncoproteins, Epidermal Growth Factor Receptor and Proliferation Markers in the Prognosis of Urinary Bladder Cancer. Pathology Research and Practice, 1997, 193, 767-775.	2.3	77
108	Comparative Assessment of Proliferating Cell Nuclear Antigen Immunostaining and of Nucleolar Organizer Region Staining in Transitional Cell Carcinomas of the Urinary Bladder. European Urology, 1992, 22, 235-240.	1.9	25